recurrent genomic alterations in patients with cll treated with venetoclax following a bcri
Published 1 year ago • 123 plays • Length 3:17Download video MP4
Download video MP3
Similar videos
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
4:51
the current frontline treatment strategy in multiple myeloma
-
3:37
progress in the categorization and treatment of lr-mds
-
4:53
understanding chronic lymphocytic leukemia (cll)
-
3:21
the cll patient journey: improving communication between physicians and patients
-
1:36
the importance of genomic testing when making treatment decisions in cll
-
1:32
genomic sequencing as a driver of advancements in pediatric hematology
-
2:19
cladribine ldac venetoclax alternated with azacitidine venetoclax in older patients with aml
-
2:13
resistance mechanisms in cll and the importance of genomic re-testing
-
1:06
key considerations when treating patients with cll who have pre-existing cardiovascular disease
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
2:08
the venice-1 trial: venetoclax monotherapy in r/r cll
-
4:38
venice i: venetoclax in r/r cll patients